アブストラクト
| Title | 4. JAK阻害薬の使い分け |
|---|---|
| Subtitle | 特集 関節リウマチ治療をめぐる話題 |
| Authors | 森信暁雄* |
| Authors (kana) | |
| Organization | *京都大学大学院医学研究科内科学講座臨床免疫学 |
| Journal | PROGRESS IN MEDICINE |
| Volume | 41 |
| Number | 1 |
| Page | 29-34 |
| Year/Month | 2021 / 1 |
| Article | 報告 |
| Publisher | ライフ・サイエンス |
| Abstract | 「はじめに」生物学的製剤の登場により関節リウマチの治療はこの20年間で劇的に変化した. 5種類の腫瘍壊死因子(TNF)-α阻害薬とバイオシミラー(バイオ後続品), 2種類のinterleukin(IL)-6受容体抗体製剤, 1種類のCD80/86阻害薬が販売されている. 3系統の生物学的製剤に加え, 現在では5剤のJanus kinase(JAK)阻害薬が承認されている. 抗体製剤は細胞外のタンパク質に結合して活性を抑制するが, JAK阻害薬は低分子化合物であり, 細胞内のリン酸化酵素であるJAKの働きを抑制する. 投与経路や作用機序は全く異なるにもかかわらず, 生物学的製剤と同等の効果を示すJAK阻害薬の使用が可能になったことで, 関節リウマチの治療は新しい段階を迎えた. 5剤のJAK阻害薬について, 臨床的有用性とその特徴について解説する. 「JAK阻害薬の作用機序」「1. サイトカインとJAK」サイトカインはその構造や受容体の構造により分類される. |
| Practice | 医学総合 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に968円(税込) です。
参考文献
- 1) Burmester GR, Bijlsma JWJ, Cutolo M, et al : Managing rheumatic and musculoskeletal diseases-past, pres-ent and future. Nat Rev Rheumatol 2017 ; 13 : 443-448.
- 2) Smolen JS, Aletaha D, McInnes IB : Rheumatoid arthri-tis. Lancet 2016 ; 388 : 2023-2038.
- 3) O'Shea JJ, Laurence A, McInnes IB : Back to the fu-ture : oral targeted therapy for RA and other autoim-mune diseases. Nat Rev Rheumatol 2013 ; 9 : 173-182.
- 4) Choy EHS, Calabrese LH : Neuroendocrine and neuro-physiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology(Oxford) 2018 ; 57 : 1885-1895.
- 5) van Vollenhoven RF, Fleischmann R, Cohen S, et al : Tofacitinib or adalimumab versus placebo in rheuma-toid arthritis. N Engl J Med 2012 ; 367 : 508-519.
残りの26件を表示する
- 6) Taylor PC, Keystone EC, van der Heijde D, et al : Baricitinib versus placebo or adalimumab in rheuma-toid arthritis. N Engl J Med 2017 ; 376 : 652-662.
- 7) Takeuchi T, Tanaka Y, Tanaka S, et al : Efficacy and safety of peficitinib(ASP015K) in patients with rheu-matoid arthritis and an inadequate response to meth-otrexate : results of a phase III randomised, double-blind, placebo-controlled trial(RAJ4) in Japan. Ann Rheum Dis 2019 ; 78 : 1305-1319.
- 8) Fleischmann R, Pangan AL, Song IH, et al : Upadac-itinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate : results of a phase iii, double-blind, ran-domized controlled trial. Arthritis Rheumatol 2019 ; 71 : 1788-1800.
- 9) Combe B, Kivitz A, Tanaka Y, et al : Efficacy and safe-ty of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate : FINCH1 primary outcome results. Ann Rheum Dis 2019 ; 78 : 77-78.
- 10) Kremer J, Li ZG, Hall S, et al : Tofacitinib in combina-tion with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis : a randomized trial. Ann Intern Med 2013 ; 159 : 253-261.
- 11) Dougados M, van der Heijde D, Chen YC, et al : Baric-itinib in patients with inadequate response or intoler-ance to conventional synthetic DMARDs : results from the RA-BUILD study. Ann Rheum Dis 2017 ; 76 : 88-95.
- 12) Tanaka Y, Takeuchi T, Tanaka S, et al : Efficacy and safety of peficitinib(ASP015K) in patients with rheu-matoid arthritis and an inadequate response to con-ventional DMARDs : a randomised, double-blind, pla-cebo-controlled phase III trial(RAJ3). Ann Rheum Dis 2019 ; 78 : 1320-1332.
- 13) Burmester GR, Kremer JM, Van den Bosch F, et al : Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to con-ventional synthetic disease-modifying anti-rheumatic drugs(SELECT-NEXT) : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018 ; 391 : 2503-2512.
- 14) Burmester GR, Blanco R, Charles-Schoeman C, et al : Tofacitinib(CP-690,550) in combination with metho-trexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis fac-tor inhibitors : a randomised phase 3 trial. Lancet 2013 ; 381 : 451-460.
- 15) Genovese MC, Kremer J, Zamani O, et al : Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 2016 ; 374 : 1243-1252.
- 16) Genovese MC, Fleischmann R, Combe B, et al : Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs(SELECT-BE-YOND) : a double-blind, randomised controlled phase 3 trial. Lancet 2018 ; 391 : 2513-2524.
- 17) Genovese MC, Kalunian K, Gottenberg JE, et al : Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refrac-tory to disease-modifying antirheumatic drug thera-py : The FINCH 2 randomized clinical trial. JAMA 2019 ; 322 : 315-325.
- 18) Lee EB, Fleischmann R, Hall S, et al : Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014 ; 370 : 2377-2386.
- 19) Fleischmann R, Schiff M, van der Heijde D, et al : Ba-ricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 2017 ; 69 : 506-517.
- 20) van Vollenhoven R, Takeuchi T, Pangan AL, et al : Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-se-verely active rheumatoid arthritis(SELECT-EAR-LY) : a multicenter, multi-country, randomized, dou-ble-blind, active comparator-controlled trial. Arthritis Rheumatol 2020 ; 72 : 1607-1620.
- 21) Westhovens R, Rigby W, van der Heijde D, et al : Ef-ficacy and safety of filgotinib for patients with rheu-matoid arthritis naive to methotrexate therapy : FINCH3 primary outcome results. Ann Rheum Dis 2019 ; 78 : 259-261
- 22) Fleischmann R, Mysler E, Hall S, et al : Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis(ORAL Strategy) : a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet 2017 ; 390 : 457-468.
- 23) Winthrop KL : The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 2017 ; 13 : 234-243.
- 24) Bechman K, Subesinghe S, Norton S, et al : A system-atic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology(Oxford) 2019 ; 58 : 1755-1766.
- 25) Harigai M, Honda S : Selectivity of Janus kinase inhib-itors in rheumatoid arthritis and other immune-medi-ated inflammatory diseases : Is expectation the root of all headache? Drugs 2020 ; 80 : 1183-1201.
- 26) Xie W, Huang Y, Xiao S, et al : Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis : systematic review and me-ta-analysis of randomised controlled trials. Ann Rheum Dis 2019 ; 78 : 1048-1054.
- 27) Sepriano A, Kerschbaumer A, Smolen JS, et al : Safety of synthetic and biological DMARDs : a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2020 : 79 : 760-770.
- 28) Xeljanz Article-20 procedure-EMA confirms Xel-janz to be used with caution in patients at high risk of blood clots. European Medicines Agency, Jun 3, 2020. (https://www.ema.europa.eu/en/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_en.pdf)
- 29) Harigai M : Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheu-matology(Oxford) 2019 ; 58(Suppl 1) : i34-i42.
- 30) Nash P, Kerschbaumer A, Dorner T, et al : Points to consider for the treatment of immune-mediated in-flammatory diseases with Janus kinase inhibitors : a consensus statement. Ann Rheum Dis 2021 ; 80 : 71-87.
- 31) Smolen JS, Landewe RBM, Bijlsma JWJ, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modify-ing antirheumatic drugs : 2019 update. Ann Rheum Dis 2020 ; 79 : 685-699.
